| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2800855401018 | 85540101 | MINOCIN CAPS 50MG/CAP ΒΤ x 24 (σε πλαστικό φιαλίδιο) (σε πλαστικό φιαλίδιο) | 2.81 | 2.95 | 04.07 |
| 05/2018 | 2800855402022 | 85540202 | MINOCIN CAPS 100MG/CAP ΒΤx12 (BLIST 1x12) | 2.93 | 03.07 | 4.23 |
For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i> and for the treatment of asymptomatic carriers of <i>Neisseria meningitidis</i>.
Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD<sub>50</sub>=2380 mg/kg (rat, oral), LD<sub>50</sub>=3600 mg/kg (mouse, oral)
Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.
11-22 hours